| Literature DB >> 29213966 |
Chan Tiel1, Felipe Kenji Sudo2, Gilberto Sousa Alves2,3, Letice Ericeira-Valente2, Denise Madeira Moreira4, Jerson Laks2,5, Eliasz Engelhardt1.
Abstract
Neuropsychiatric symptoms or Behavioral and Psychological Symptoms of Dementia (BPSD) are common and invariably appear at some point during the course of the disease, mediated both by cerebrovascular disease and neurodegenerative processes. Few studies have compared the profiles of BPSD in Vascular Cognitive Impairment (VCI) of different subtypes (subcortical or cortical) and clinical stages (Vascular Cognitive Impairment No Dementia [VaCIND] and Vascular Dementia [VaD]).Entities:
Keywords: Alzheimer's disease; BPSD; NPI; Vascular Cognitive Impairment; Vascular Dementia; neuropsychiatric symptoms
Year: 2015 PMID: 29213966 PMCID: PMC5619363 DOI: 10.1590/1980-57642015DN93000004
Source DB: PubMed Journal: Dement Neuropsychol ISSN: 1980-5764
Figure 1Flowchart of search strategy and article selection.
RCT: Randomized clinical trial; AD: Alzheimer’s Disease; NPI: Neuropsychiatric Inventory; DLB: Dementia with Lewy Bodies; FTD: Frontotemporal dementia; VCI: Vascular Cognitive Impairment; VaD: Vascular Dementia.
Characteristics of samples, diagnostic groups and operational criteria in the studies selected.
| Year | Diagnosis | n | Diagnostic criteria | References |
|---|---|---|---|---|
| 2007 | V-CIND + VaD + MD (AD+VaD) | 157 | DSM-IV, CDR, HIS | Chiu et al.[ |
| 2010 | VaD | 484 | DSM-IV, NINDS-AIREN | Staekenborg et al.[ |
| 2012 | SVD + V-CIND | 73 | DSM-IV, Fazekas, CDR | Chin et al.[ |
| 2013 | SVD + V-CIND | 127 | DSM-IV, Fazekas, CDR | Kim et al.[ |
| 2013 | VaD + V-CIND | 60 | NINDS-AIREN, DSM-IV, HiS, CDR | Gupta et al.[ |
| 2013 | VaD | 51 | NINDS-AIREN,DSM-IV | Pan et al.[ |
| 2014 | VaD + V-CIND | 60 | NINDS-AIREN, CSHA | Gupta et al.[ |
| 2000 | AD + VaD | 329 | DSM-IV, NINDS-AIREN, CDR | Lyketsos et al.[ |
| 2005 | AD + VaD (cortical + subcortical) | 536 | DSM-IV, NINCDS-ADRDA, CDR | Fuh et al.[ |
| 2009 | AD + VaD | 154 | DSM-IV, CDR, NINCDS-AIREN | Hsieh et al.[ |
| 2008 | AD + VaD (cortical + subcortical) | 65 | DSM-IV, NINCDS-ADRDA, HIS | Fernández-Martínez et al.[ |
| 2012 | AD + VaD | 302 | DSM-IV, NINCDS-ADRDA, NINDS-AIREN | D’onófrio et al.[ |
| 2014 | AD + VaD (cortical + subcortical) | 100 | DSM-IV, NINDS-AIREN | Bandyopadhyay et al.[ |
AD: Alzheimer Dementia; VaD: Vascular Dementia; MD: Mixed Dementia; SVD: Subcortical Vascular Dementia; VCIND: Vascular cognitive Impairment-No Dementia; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders 4th edition; CDR: Clinical Dementia Rating; HIS: Hachinski ischaemic Score; Fazekas: Fazekas scale; CSHA: Canadian Study of Health and Ageing; NINDS-AIREN: National Institute of Neurological Disorders and Stroke and Association - Internationale pour la Recherché et lÉnseignement en Neurosciences; NINCDS-ADRDA: National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association.
Comparison of mean NPI subitem scores in studies assessing VCI subjects.
| References (n) | Del | Hal | Agi | Dep | Anx | Eup | Apa | Dis | Irr | Ama | Sle | App | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fuh et al., 2005[ | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) | |
| Chiu et al., 2007[ | 1.7 (3.6) | 1.6 (3.5) | 2.1 (3.8) | 2.8 (4.0) | 1.9 (3.6) | 0.4 (1.5) | 4.6 (5.3) | 0.9 (2.5) | 2.9 (4.3) | 2.3 (4.4) | 5.2 (5.1) | 2.5 (4.1) | 27.7 (22.2) |
| Fernández-Martínes et al., 2008[ | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) 31.8%] | (--) | 11.82 (9.75) | ||
| Staekenborg et al., 2010[ | 0.4 (1.4) | 0.1 (1.3) | 1.1 (3.0) | 1.4 (2.5) | 1.1 (3.1) | 0.1 (1.0) | 3.8 (3.4) | 0.5 (1.6) | 1.2 (2.1) | 0.6 (1.6) | 1.1 (2.8) | 1.4 (2.3) | --(--) |
| Chin et al., 2012[ | 0.31 (1.14) | 0.33 (1.32) | 1.40 (1.96) | 1.33 (1.78) | 1.43 (1.48) | 0.31 (1.32) | 3.86 (4.00) | 1.00 (2.48) | 2.10 (2.62) | 2.26 (4.20) | 2.21 (3.73) | 2.40 (3.68) | 18.95 (16.18) |
| Kim et al., 2013[ | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) |
| Gupta et al., 2014[ | 1.7 | 0.1 | 3.9 | 6.0 | 4.0 | 0.0 | 5.9 | 0.4 | 4.2 | 2.8 | 3.7 | 4.3 | (--) |
| Lyketsos et al., 2000[ | 0.29 (0.96) | 1.10 (2.03) | 0.57 (1.70) | 0.10 (0.79) | 0.43 (3.30) | 0.52 (1.80) | 0.41 (0.94) | 0.19 (0.76) | --(--) | --(--) | 7.70 (13.50) | ||
| Fuh et al., 2005[ | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) | ||
| Fernández-Martínes et al., 2008[ | 0.75 (2.44) | 0.43 (2.27) | 0.96 (2.27) | 0.96 (1.86) | 0.96 (1.64) | 0.14 (0.59) | 4.11 (3.85) | 0.54 (1.29) | 1.75 (2.95) | 0.29 (1.05) | 11.82 (9.75) | ||
| Hsieh et al, 2008[ | 2.46 (4.34) | 1.46 (2.77) | 1.73 (3.19) | 3.30 (2.81) | 1.23 (2.05) | 2.00 (3.09) | 5.04 (2.90) | 0.00 (0.00) | 0.92 (1.89) | 3.31 (3.08) | 0.00 (0.00) | 26.69 (9.92) | |
| Staekenborg et al., 2010[ | 0.3 (1.5) | 0.0 (0.1) | 1.5 (2.3) | 1.1 (1.6) | 1.5 (2.3) | 0.2 (0.7) | 2.1 (2.9) | 0.4 (1.1) | 1.7 (2.5) | 0.2 (0.9) | 1.0 (2.8) | 1.5 (2.4) | (--) |
| D’onófrio et al. 2012[ | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) | ||
| Gupta et al., 2013[ | 0.96 | 0.09 | 3.81 | 6.53 | 3.03 | 0.28 | 5.37 | 0.5 | 4.18 | 1.78 | 3.28 | 4.43 | (--) |
| Pan et al., 2013[ | 1.55 (0.69) | 1.30 (0.51) | 5.55 (0.90) | 4.21 (0.81) | 2.32 (0.81) | 3.75 (0.65) | 3.33 (0.71) | 2.75 (0.68) | 3.2 (0.92) | 4.25 (0.69) | 5.32 (0.83) | 4.08 (0.57) | -- (--) |
| Gupta et al., 2014[ | 0.5 | 0.2 | 3.8 | 6.1 | 2.3 | 0.7 | 1.9 | 0.6 | 4.8 | 0.9 | 1.8 | 3.5 | (--) |
| Bandyopadhyay et al., 2014[ | (--) | (--) | (--) | (--) | (--) | ||||||||
| Chin et al., 2012[ | 0.00 (0.00) | 0.00 (0.00) | 0.55 (1.73) | 0.26 (0.58) | 0.39 (0.76) | 0.03 (0.18) | 1.00 (2.14) | 0.23 (1.09) | 0.52 (1.29) | 0.52 (1.29) | 0.19 (0.65) | 0.10 (0.54) | 3.26 (5.64) |
| Kim et al., 2013[ | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) | (--) |
| Chiu et al., 2007[ | 0.7 (1.8) | 0.0 (0.2) | 0.5 (1.6) | 1.4 (2.5) | 0.9 (1.9) | 0.1 (0.3) | 1.7 (3.7) | 0.3 (1.9) | 1.3 (2.6) | 0.2 (1.3) | 5.1 (5.4) | 1.7 (3.4) | 13.5 (11.6) |
| Gupta et al., 2013[ | 0.6 | 0.07 | 2.25 | 4.6 | 2.5 | 0.5 | 0.46 | 0.25 | 3.14 | 0.96 | 0.82 | 2.1 | -- (--) |
Values expressed as mean (standard deviation). VaD: Vascular dementia; CIND: Cognitive Impairment No-Dementia; Del: Delusions; Hal: Hallucinations; Agi: Agitation; Dep: Depression; Anx: Anxiety; Eup: Euphoria; Apa: Apathy; Dis: Disinhibition; Irr: Irritability; Ama: Aberrant motor activity; Sle: Sleep disturbance; App: Eating disorder.
VaD diagnosed according to NINDS-AIREN criteria. Values in bold were significantly different from scores in AD subjects.
Comparison of mean Neuropsychiatric Symptom prevalences among SVaD, CSVaD and VaCIND groups.
| Neuropsychiatric symptoms | SVaD (n=810) | CSVaD (n=557) | VaCIND (n=159) | p-value | Post-hoc |
|---|---|---|---|---|---|
| Delusion | 19.68 (10.68) | 16.16 (8.78) | 12.18 (9.09) | .519 | – |
| Hallucination | 10.79 (10.06) | 12.21 (9.92) | 1.85 (1.78) | .272 | – |
| Agitation | 33.45 (14.30) | 41.33 (13.34) | 16.30 (7.53) | .036 | CSVaD≠VaCIND |
| Depression | 52.63 (15.69) | 53.34 (15.50) | 45.94(23.40) | .798 | – |
| Anxiety | 36.37 (10.28) | 36.09 (10.53) | 31.28(10.61) | .759 | – |
| Euphoria | 5.41 (5.30) | 9.99 (10.20) | 3.04 (3.68) | .350 | – |
| Apathy | 49.02 (19.78) | 50.24 (16.21) | 17.14 (8.86) | .025 | CSVaD≠VaCIND; SVaD≠VaCIND |
| Disinhibition | 17.27 (9.11) | 10.83 (11.11) | 6.88 (1.76) | .254 | – |
| Irritability | 38.23 (12.21) | 40.34 (19.32) | 34.08 (8.73) | .839 | – |
| Motor alterations | 17.60 (14.28) | 22.47 (17.23) | 5.43 (7.73) | 2.73 | – |
| Sleeping alterations | 33,47 (21,90) | 44.85 (22.94) | 26.13(28.83) | .447 | – |
| Appetite alterations | 37.98 (20.76) | 40.23 (28.20) | 26.82(14.83) | .710 | – |
| Total | 92.53 (4.55) | 88.07 (16.42) | 73.83(22.89) | .226 | – |
BPSD: Behavioral and Psychological Symptoms of Dementia; SVaD: Subcortical Vascular Dementia; CSVaD: Cortical-subcortical Vascular Dementia; VaCIND: Vascular Cognitive Impairment No-Dementia.